I love 20/20 hindsight stories. It's so easy to ma
Post# of 30028
Posted On: 10/18/2014 11:11:32 AM
I love 20/20 hindsight stories. It's so easy to make the "AMBS is the next AMGN" comparison. All you have to do is type it or say it and it automatically make it sound true! Let's put out some facts here. AMGEN was cofounded by 4 people. Dr. Rubenfeld was at AMGEN for ~3 years and left in 1983. Epogen got approved for kidney disease in 1989 and then for cancer in 1993. A lot of what happened at AMGEN had nothing to do with Rubinfeld because he was long gone and working on things not related to anything AMGEN was doing. Let's get that straight. Please look it up yourself as I know you won't believe me.
And while I know many of your are having the typical knee jerk reaction to what I post with your face turning red and steam comoing our of your ears, I have no idea what will come of AMBS. That path of AMGN has no correlation to AMBS because the comparison can be used with ANY biotech out there. AMGEN is unique and the odds of any other company duplicating what AMGEN has quite small.
Now, Dr. Rubinfeld is a smart guy. I think it's great he is advising Gerald and the company and that he sees promise with MANF. He's had tremendous success starting and building biotech companies. And hopefully he'll be able to witness AMBS grow like AMGN, Supergen and others. But people need to stop saying AMBS is the next AMGN. Also remember it took AMGEN a LOOOOOONG time before it started to see substantial growth.
Look at it's chart. AMGN became AMGN because its drugs made it through the grueling FDA clinical trials and targets large markets. AMBS has yet to even prove MANF works in living humans. One step at a time. Hopefully one day we can all say AMBS was the investment of a lifetime but right now, the company has a lot to prove.
And while I know many of your are having the typical knee jerk reaction to what I post with your face turning red and steam comoing our of your ears, I have no idea what will come of AMBS. That path of AMGN has no correlation to AMBS because the comparison can be used with ANY biotech out there. AMGEN is unique and the odds of any other company duplicating what AMGEN has quite small.
Now, Dr. Rubinfeld is a smart guy. I think it's great he is advising Gerald and the company and that he sees promise with MANF. He's had tremendous success starting and building biotech companies. And hopefully he'll be able to witness AMBS grow like AMGN, Supergen and others. But people need to stop saying AMBS is the next AMGN. Also remember it took AMGEN a LOOOOOONG time before it started to see substantial growth.
Look at it's chart. AMGN became AMGN because its drugs made it through the grueling FDA clinical trials and targets large markets. AMBS has yet to even prove MANF works in living humans. One step at a time. Hopefully one day we can all say AMBS was the investment of a lifetime but right now, the company has a lot to prove.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
My Agenda: To see Amarantus prosper so I can make a nice return on my investment.
Scroll down for more posts ▼